Steroid-refractory Acute Graft-versus-Host Disease Clinical Trial
Official title:
A Phase I Study of Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease (SR-aGVHD) or Treatment-refractory Acute Graft-versus-host Disease (TR-aGVHD)
Verified date | January 2023 |
Source | AltruBio Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A Phase I study to establish the pharmacokinetics, pharmacodynamics, safety and efficacy profiles of Neihulizumab in patients with steroid-refractory or treatment refractory acute graft-versus-host disease (SR/TR-aGVHD)
Status | Completed |
Enrollment | 37 |
Est. completion date | December 31, 2022 |
Est. primary completion date | September 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years and older |
Eligibility | Inclusion Criteria (must meet all of the following criteria): 1. Patients must have clinical aGVHD and pathologic findings consistent with the diagnosis by biopsy of at least 1 involved site, and 1. progressed after 3 days of treatment with methylprednisolone (MP) 2 mg/kg/day equivalent, or 2. did not improve after 7 days of treatment with MP 2 mg/kg/day equivalent, or 3. progressed to involve a new organ after treatment with MP 1 mg/kg/day equivalent for skin and upper gastrointestinal (GI) GVHD, or 4. recurred during or after a steroid taper 2. For single dose phase: Patients must have erythematous manifestations of cutaneous aGVHD. Characteristics of the rash must indicate active inflammation (red coloration) as distinct from resolving inflammation (brown coloration). 3. For single dose phase: Providers and patients must be willing to defer new systemic or cutaneous topical treatment of aGVHD for at least 36 hr after administration of Neihulizumab. 4. Patient must give informed consent and sign an approved consent form prior to any study procedures. 5. Females of childbearing potential must have a negative pregnancy test result before enrollment. Males and females of childbearing potential must agree to use a highly effective method of birth control during the study for at least 30 days after enrollment in the study. Exclusion Criteria (may not meet any of the following criteria): 1. For single dose phase: Prior administration of anti-lymphocyte globulin or anti- thymocyte globulin for treatment of aGVHD. 2. For multiple dose phase: Has received any systemic treatment in addition to corticosteroids for aGVHD. 3. Stage 4 lower GI GVHD, defined by the presence of ileus, severe abdominal pain, or overt GI bleeding. 4. Uncontrolled infections not responding to antimicrobial therapy or requiring intensive critical care or vasopressors. 5. Evidence of end-organ cytomegalovirus (CMV) or adenovirus infection. 6. Known to have adenovirus, or Epstein Barr virus (EBV) viremia from screening according to institutional standard practice. Patients receiving appropriate antiviral treatment for CMV, HHV6 or hepatitis viremia are eligible on a case-by-case basis. 7. HIV infection or a known HIV-related malignancy. 8. Tuberculosis, history of tuberculosis or a known positive Quantiferon test for tuberculosis. 9. Unplanned donor lymphocyte infusion (DLI) for residual or relapsed malignancy or mixed chimerism. DLI as part of the planned HCT protocol is allowed. 10. Known relapsed or progressive malignancy after transplant, posttransplant lymphoproliferative disease or any secondary malignancy diagnosed after HCT. 11. Absolute neutrophil count (ANC) <1000/mm3. 12. Total serum bilirubin concentration >3.0 mg/dL UNLESS attributed to GVHD. 13. Creatinine clearance < 30 mL/min calculated by Cockcroft-Gault equation. 14. Sodium (Na) concentration < 130 mmol/L. 15. Karnofsky Performance Status (KPS) or Lansky Performance Status < 20%. 16. Intensive care unit (ICU) care, life expectancy of less than 28 days, ongoing or unresolved hepatic sinusoidal obstruction syndrome, unstable hemodynamics, or evidence of current or previous clinically significant disease, medical condition or finding (including vital signs and ECG) that in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data. 17. History of allergy or hypersensitivity to any systemically administered antibody agent or its excipients. 18. Pregnancy or nursing. 19. Less than 12 years of age. |
Country | Name | City | State |
---|---|---|---|
United States | University of Michigan | Ann Arbor | Michigan |
United States | Emory University | Atlanta | Georgia |
United States | Dana Farber Cancer Center | Boston | Massachusetts |
United States | University of Chicago | Chicago | Illinois |
United States | University Hospitals Seidman Cancer Center | Cleveland | Ohio |
United States | City of Hope | Duarte | California |
United States | Baylor College of Medicine-Houston Methodist & Texas Children's Hospital | Houston | Texas |
United States | David Geffen School of Medicine at UCLA | Los Angeles | California |
United States | University of Miami - Sylvester Comprehensive Cancer Center | Miami | Florida |
United States | Medical College of Wisconsin | Milwaukee | Wisconsin |
United States | University of Minnesota | Minneapolis | Minnesota |
United States | Fred Hutchinson Cancer Research Center | Seattle | Washington |
United States | The University of Kansas Cancer Center | Westwood | Kansas |
Lead Sponsor | Collaborator |
---|---|
AltruBio Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pharmacokinetics of Neihulizumab - AUC | Including AUC0-t, AUC0-tz, AUC 0-inf | Up to Day 56 | |
Primary | Pharmacokinetics of Neihulizumab - Cmax | Maximum plasma concentration | Up to Day 56 | |
Primary | Pharmacokinetics of Neihulizumab - tmax | Time to reach Cmax | Up to Day 56 | |
Primary | Pharmacokinetics of Neihulizumab - Lambda-z | Terminal phase elimination rate constant | Up to Day 56 | |
Primary | Pharmacokinetics of Neihulizumab - t1/2 | Half life | Up to Day 56 | |
Primary | Pharmacokinetics of Neihulizumab - MRT | Mean Residence Time | Up to Day 56 | |
Primary | Pharmacokinetics of Neihulizumab - Vz and Vss | Volume of distribution and volume of distribution at steady state | Up to Day 56 | |
Secondary | Adverse Events (AEs) | AEs graded according to CTCAE v4.03 | Up to Day 180 | |
Secondary | To measure the Receptor Occupancy (RO) | Receptor occupancy will be monitored using a flow cytometry based method | Up to Day 56 | |
Secondary | To measure regenerating islet-derived 3-alpha (REG3a) and suppression of tumorigenicity 2 (ST2) as Pharmacodynamics (PD) biomarkers. | Receptor occupancy will be monitored using a flow cytometry based method | Up to Day 56 | |
Secondary | Complete Response (CR) | To assess the rate of complete response (CR) at Day 28 in patients treated with Neihulizumab | Day 28 | |
Secondary | Overall Response Rate (ORR) | To assess the Overall Response Rate (ORR) at Day 28: CR+PR | Day 28 | |
Secondary | Duration of Response | For subjects with CR at Day 28, duration of response will be assessed according to the time interval from Day 28 to the first occurrence of (1) resumption of Neihulizumab administration or initiation of new systemic treatment for aGvHD or (for patients who have tapered steroids) an increase in corticosteroids to methylprednisolone 2 mg/kg (+/-10%) equivalent or more, or (2) death. | Up to Day 180 | |
Secondary | Non Relapse Mortality (NRM) | Patients will be followed-up for survival for 6 months after the first Neihulizumab treatment | Day 180 | |
Secondary | Immunogenicity | Immunogenicity will be monitored by anti-drug antibody (ADA) ELISA | Up to Day 56 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06075706 -
Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease
|
Phase 2 | |
Recruiting |
NCT04629833 -
Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy
|
Phase 3 |